Methods for Diagnosing Colon, Stomach, Prostate and Pancreas Cancer Using miR-223

1 .- 33 . (canceled)

34 . A method of diagnosing whether a subject has, or is at risk for developing, a solid cancer, comprising:

a.) comparing the level of at least miR-223 gene products in a test sample to a control level of at least miR-223 gene products; and

b.) diagnosing whether the subject has, or is at risk for developing, a solid cancer other than breast or lung cancer if the level of at least miR-223 gene products in the test sample from the subject is greater than the level of miR-223 gene products of the control.

35 . A method of diagnosing whether a subject has, or is at risk for developing, a solid cancer, comprising:

a.) reverse transcribing at least miR-223 from a test sample obtained from the subject to provide at least miR-223 target oligonucleotides;

b.) hybridizing at least the miR-223 target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides that include at least miR-223 RNA specific probe oligonucleotides to provide a hybridization profile for the test sample;

c.) comparing the test sample hybridization profile to at least one control hybridization profile; and

d.) diagnosing whether the subject has, or is at risk for developing, a solid cancer selected from the group consisting of: colon cancer; stomach cancer; pancreas cancer; and prostate cancer, if the level of at least miR-223 gene products in the test sample from the subject is greater than the level of miR-223 gene products of the control.

36 . The method of claim 34 , which further comprises comparing the level of at least one additional miR gene product in a test sample from the subject to a control level of the miR gene product, wherein the at least one additional miR gene product is selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.

37 . The method of claim 34 , which further comprises comparing the level of at least two additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least two additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.

38 . The method of claim 34 , which further comprises comparing the level of at least three additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least three additional miR gene products are selected from the group consisting of miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.

39 . The method of claim 34 , which further comprises comparing the level of at least four additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least four additional miR gene products are selected from the group consisting of miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.

40 . The method of claim 34 , which further comprises comparing the level of at least five additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least five additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.

41 . The method of claim 34 , wherein the solid cancer is colon cancer.

42 . The method of claim 34 , wherein the solid cancer is stomach cancer.

43 . The method of claim 34 , wherein the solid cancer is pancreas cancer.

44 . The method of claim 34 , wherein the solid cancer is prostate cancer.

45 . The method of claim 34 , wherein the solid cancer is colon cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-24-1; miR-29b-2; miR-20a; miR-10a; miR-32; miR-203; miR-106a; miR-17-5p; miR-30c; miR-223; miR-126; miR-128b; miR-21; miR-24-2; miR-99b prec; miR-155; miR-213; miR-150; miR-107; miR-191; miR-221; and miR-9-3.

46 . The method of claim 34 , wherein the solid cancer is stomach cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-223; miR-21; miR-218-2; miR-103-2; miR-92-2; miR-25; miR-136; miR-191; miR-221; miR-125b-2; miR-103-1; miR-214; miR-222; miR-212 prec; miR-125b-1; miR-100; miR-107; miR-92-1; miR-96; miR-192; miR-23a; miR-215; miR-7-2; miR-138-2; miR-24-1; miR-99b; miR-33b; and miR-24-2.

47 . The method of claim 34 , wherein the solid cancer is pancreas cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-103-2; miR-103-1; miR-24-2; miR-107; miR-100; miR-125b-2; miR-125b-1; miR-24-1; miR-191; miR-23a; miR-26a-1; miR-125a; miR-130a; miR-26b; miR-145; miR-221; miR-126; miR-16-2; miR-146; miR-214; miR-99b; miR-128b; miR-155; miR-29b-2; miR-29a; miR-25; miR-16-1; miR-99a; miR-224; miR-30d; miR-92-2; miR-199a-1; miR-223; miR-29c; miR-30b; miR-129-1/2; miR-197; miR-17-5p; miR-30c; miR-7-1; miR-93-1; miR-140; miR-30a-5p; miR-132; miR-181b-1; miR-152 prec; miR-23b; miR-20a; miR-222; miR-27a; miR-92-1; miR-21; miR-129-1/2 prec; miR-150; miR-32; miR-106a; and miR-29b-1.

48 . The method of claim 34 , wherein the solid cancer is prostate cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: let-7d; miR-128a prec; miR-195; miR-203; let-7a-2 prec; miR-34a; miR-20a; miR-218-2; miR-29a; miR-25; miR-95; miR-197; miR-135-2; miR-187; miR-196-1; miR-148; miR-191; miR-21; let-71; miR-198; miR-199a-2; miR-30c; miR-17-5p; miR-92-2; miR-146; miR-181b-1 prec; miR-32; miR-206; miR-184 prec; miR-29a prec; miR-29b-2; miR-149; miR-181b-1; miR-196-1; miR-93-1; miR-223; miR-16-1; miR-101-1 prec; miR-124a-1; miR-26a-1; miR-214; miR-27a; miR-24-1; miR-106a; and miR-199a-1.